Iope, a clinical-grade skincare brand under Amorepacific, has entered the US market through strategic retail partnerships at Sephora.

Backed by 30 years of research and expertise, Iope emerged as a leader in Korean anti-aging innovation. This US expansion marks the brand’s second global market and its first international push.

Giovanni Valentini, CEO of Amorepacific North America, said the debut follows decades of the skincare label’s “unparalleled performance” in Korea.

“Consumers are more discerning than ever, prioritizing clinically proven efficacy and visible results in an increasingly saturated skincare market. 

“With Iope, we are introducing targeted skincare solutions that are clinically tested, at a competitive price point,” he added.

For three decades, the brand has been at the forefront of advancements in key active ingredients, with its technical development supported by 26 Korean patents and over a dozen scientific publications.

Through this entry, Iope will bring its nine targeted products to US consumers, spanning XMD, Retinol RX, Vitamin C, and PDRN Caffeine collections. The brand draws on Korea’s “clinically proven” skin booster treatments for its latest innovations, claiming to deliver “professional treatment-level results at home”.

Iope’s products, which range in price from $6.50 for a single sheet mask to $69 for XMD Stem III Clinical Recovery Cream, are available on Sephora’s website and will roll out to stores starting March 13.

• Further reading: Mac Cosmetics launches in Sephora US and Sephora at Kohl’s.